Gamgee

Category

Other

Launched

August 12, 2026

Stage

Unknown

Website

gamgee.io

When Paul Conyngham's dog Rosie was diagnosed with mast cell cancer, the vets gave her months to live. Surgery, chemotherapy, and immunotherapy all failed. So Conyngham, a tech entrepreneur with no medical background, did something extraordinary: he used AI tools like ChatGPT and AlphaFold to design a personalised mRNA vaccine for his dog. The treatment added two more years to Rosie's life. Now, that DIY experiment has become Gamgee, a startup with backing from Y Combinator and Founders Fund, and a waitlist of over 300 dogs. Gamgee's pitch is simple and audacious: input the tumour, output the vaccine. The company develops personalised mRNA cancer vaccines for dogs, built from the dog's own tumour tissue. It's a concept borrowed from human oncology, where mRNA vaccines are being tested against cancers like melanoma and lung cancer. But Gamgee is applying it to pets, and it's doing so with a speed and accessibility that human trials rarely achieve. This article examines how Gamgee is turning a heart wrenching personal story into a scalable biotech venture, and why that journey is both promising and fraught with challenges.